



Perspectives for Pharmacy Practice:

Improving the Management of Epithelioid Sarcoma in the Era of Disease-Specific Therapy

SUGGESTED READINGS

- Blay JY, Soibinet P, Penel N, et al. Improved survival using specialized multidisciplinary board in sarcoma patients. *Ann Oncol.* 2017;28:2852-2859. doi:10.1093/annonc/mdx484
- Brennan MF, Antonescu CR, Maki RG. Epithelioid sarcoma. In: Brennan MF, Antonescu CR, Maki RG. *Management of Soft Tissue Sarcoma.* 2016:237-241. doi:10.1007/978-1-4614-5004-7_1
- Chbani L, Guillou L, Terrier P, et al. Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. *Am J Clin Pathol.* 2009;131:222-227. doi:10.1309/AJCPU98ABIPVJAIV
- Choi J, Ro J. The 2020 WHO Classification of Tumors of Soft Tissue: selected changes and new entities. *Adv Anat Pathol.* 2021;28:44-58. doi:10.1097/PAP.0000000000000284
- Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. *WHO Classification of Tumours of Soft Tissue and Bone.* 4th ed. World Health Organization; 2013.
- Gounder M, Merriam P, Ratan R, et al. Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma [abstract 1687P]. *Ann Oncol.* 2019;30(suppl 5):v692. doi:10.1093/annonc/mdz283.020
- Gounder M, Schöffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. *Lancet Oncol.* 2020;21:1423-1432. doi:10.1016/S1470-2045(20)30451-4
- Hornick J, Cin PD, Fletcher CDM. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. *Am J Surg Pathol.* 2009;33:542-550. doi:10.1097/PAS.0b013e3181882c54
- Italiano A, Soria J-C, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. *Lancet Oncol.* 2018;19:649-659. doi:10.1016/S1470-2045(18)30145-1
- Jawad MU, Extein J, Min ES, Scully SP. Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database. *Clin Orthop Relat Res.* 2009;467:2939-2948. doi:10.1007/s11999-009-0749-2
- Kohashi K, Oda Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. *Cancer Sci.* 2017;108:547-552. doi:10.1111/cas.13173
- National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Soft tissue sarcoma. V3.2021. Accessed February 22, 2022. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. *CA Cancer J Clin.* 2021;71:7-33. doi:10.3322/caac.21654
- Siegel R, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* 2022;72:7-33. doi:10.3322/caac.21708
- Simeone N, Frezza AM, Zaffaroni N, Stacchiotti S. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives. *Future Oncol.* 2021;17:1253-1263. doi:10.2217/fon-2020-0781
- Singer N, Caplan A. Mesenchymal stem cells: mechanisms of inflammation. *Annu Rev Pathol.* 2011;6:457-478. doi:10.1146/annurev-pathol-011110-130230
- Stacchiotti S, Schöffski P, Jones R, et al. Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950) [abstract 11003]. *J Clin Oncol.* 2019;37(15 suppl):11033. doi:10.1200/JCO.2019.37.15_suppl.11003
- Tazemetostat PI. Epizyme, Inc.; 2020.
- Thway K, Jones RL, Noujaim J, Fisher C. Epithelioid sarcoma: diagnostic features and genetics. *Adv Anat Pathol.* 2016;23:41-49. doi:10.1097/PAP.0000000000000102